LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Lewis, Joseph M.; Sloan, Derek James (2015)
Publisher: Dove Press
Languages: English
Types: Article
Subjects: RS, R5-920, Tuberculosis, Chemical Health and Safety, RA0421, Safety Research, Therapeutics and Clinical Risk Management, Pharmacology, Toxicology and Pharmaceutics(all), OPC-67683, qw_45, MDR-TB, Review, RS Pharmacy and materia medica, Medicine (General), RA0421 Public health. Hygiene. Preventive Medicine, wf_200, Delamanid, Medicine(all), Drug resistance, Pharmacology (medical)

Classified by OpenAIRE into

mesheuropmc: education
Joseph M Lewis,1 Derek J Sloan2,3 1Tropical and Infectious Disease Unit, Royal Liverpool University Hospital, Liverpool, UK; 2Liverpool School of Tropical Medicine, Pembroke Place, Liverpool, UK; 3Liverpool Heart and Chest Hospital, Liverpool, UK Abstract: Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management. Keywords: delamanid, OPC-67683, tuberculosis, drug resistance, MDR-TB